Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Fresh Meadows, New York 11365


The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.


Main Inclusion Criteria: - ≥ 18 years of age, - Receiving stable maintenance hemodialysis 3 times a week - On restricted phosphate diet at screening and throughout study - Receiving stable dose of phosphate binder for at least 1 month - Serum phosphate levels >1.78 mmol/L Main Exclusion Criteria: - Uncontrolled hyperphosphatemia - Hypercalcemia at screening or during washout - Serum calcium < 1.9 mmol/L (<7.6 mg/dL) - Severe hyperparathyroidism (iPTH levels >600 ng/L) - Pregnancy or lactation - Iron deficiency anemia - History of hemochromatosis or ferritin >800 mg/L, - Hepatitis B, hepatitis C or other significant concurrent liver disorders - Known positivity to HIV - Use of oral iron preparations 1 month before screening, - Serious medical condition or uncontrolled systemic disease



Primary Contact:

Principal Investigator
Prof. Rudolf P Wutrich, MD

Backup Contact:


Location Contact:

Fresh Meadows, New York 11365
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.